Molecular basis of the interactions between the p73 N terminus and p300: Effects on transactivation and modulation by phosphorylation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 9, 2009, Pages 3142-3147

  Burge, Sarah ^a   Teufel, Daniel P ^a   Townsley, Fiona M ^a   Freund, Stefan M V ^a   Bycroft, Mark ^a   Fersht, Alan R ^a  

^a MRC CENTRE FOR PROTEIN ENGINEERING   (United Kingdom)

Author keywords

p73; Transcription

Indexed keywords

MUTANT PROTEIN; PROTEIN MDM2; PROTEIN P300; PROTEIN P73; SMALL INTERFERING RNA;

ANIMAL CELL; ANISOTROPY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOMETRY; DISSOCIATION CONSTANT; FLUORESCENCE ANALYSIS; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; TRANSACTIVATION;

AMINO ACID SEQUENCE; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CONSERVED SEQUENCE; DNA-BINDING PROTEINS; E1A-ASSOCIATED P300 PROTEIN; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEIN BINDING; SEQUENCE ALIGNMENT; THERMODYNAMICS; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 62549085237     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0900383106     Document Type: Article

References (42)

1. Harms K, Nozell S, Chen X (2004) The common and distinct target genes of the p53 family transcription factors. Cell Mol Life Sci 61:822-842.
2. Zaika AI, et al. (2002) ΔNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 196:765-780.
3. Maisse C, Munarriz E, Barcaroli D, Melino G, De Laurenzi V (2004) DNA damage induces the rapid and selective degradation of the ΔNp73 isoform, allowing apoptosis to occur. Cell Death Differ 11:685-687.
4. YangA, et al. (2000) p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404:99-103.
5. Melino G, De Laurenzi V, Vousden KH (2002) p73: Friend or foe in tumorigenesis. Nat Rev Cancer 2:605-615.
6. Ramadan S, et al. (2005) p73 induces apoptosis by different mechanisms. Biochem Biophys Res Commun 331:713-717.
7. Goodman RH, Smolik S (2000) CBP/p300 in cell growth, transformation, and development. Genes Dev 14:1553-1577.
8. Giles RH, Peters DJ, Breuning MH (1998) Conjunction dysfunction: CBP/p300 in human disease. Trends Genet 14:178-183.
9. Zeng XY, et al. (2000) The N-terminal domain of p73 interacts with the CH1 domain of p300/CREB binding protein and mediates transcriptional activation and apoptosis. Mol Cell Biol 20:1299-1310.
10. Zeng X, Lee H, Zhang Q, Lu H (2001) p300 does not require its acetylase activity to stimulate p73 function. J Biol Chem 276:48-52.
11. Teufel DP, Freund SM, Bycroft M, Fersht AR (2007) Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53. Proc Natl Acad Sci USA 104:7009-7014.
12. Zhu J, Zhou W, Jiang J, Chen X (1998) Identification of a novel p53 functional domain that is necessary for mediating apoptosis. J Biol Chem 273:13030-13036.
13. Liu G, Xia T, Chen X (2003) The activation domains, the proline-rich domain, and the C-terminal basic domain in p53 are necessary for acetylation of histones on the proximal p21 promoter and interaction with p300/CREB-binding protein. J Biol Chem 278:17557-17565.
14. Zhu J, Zhang S, Jiang J, Chen X (2000) Definition of the p53 functional domains necessary for inducing apoptosis. J Biol Chem 275:39927-39934.
15. De Guzman RN, Liu HY, Martinez-Yamout M, Dyson HJ, Wright PE (2000) Solution structure of the TAZ2 (CH3) domain of the transcriptional adaptor protein CBP. J Mol Biol 303:243-253.
16. Kussie PH, et al. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274:948-953.
17. Campbell KM, Lumb KJ (2002) Structurally distinct modes of recognition of the KIX domain of CBP by Jun and CREB. Biochemistry 41:13956-13964.
18. Oltvai ZN, Milliman CL, Korsmeyer SJ (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609-619.
19. Melino G, et al. (2004) p73 induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J Biol Chem 279:8076-8083.
20. Irwin MS, et al. (2003) Chemosensitivity linked to p73 function. Cancer Cell 3:403-410.
21. Fakharzadeh SS, Trusko SP, George DL (1991) Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 10:1565-1569.
22. Momand J, Zambetti GP, Olson DC, George D, Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245.
23. Kubbutat MH, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387:299-303.
24. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296-299.
25. Zeng X, et al. (1999) MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol 19:3257-3266.
26. Toledo F, Wahl GM (2006) Regulating the p53 pathway: In vitro hypotheses, in vivo veritas. Nat Rev Cancer 6:909-923.
27. Bode AM, Dong Z (2004) Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4:793-805.
28. Paliwal P, Radha V, Swarup G (2007) Regulation of p73 by Hck through kinase-dependent and -independent mechanisms. BMC Mol Biol 8:45.
29. Jones EV, Dickman MJ, Whitmarsh AJ (2007) Regulation of p73-mediated apoptosis by c-Jun N-terminal kinase. Biochem J 405:617-623.
30. Costanzo A, et al. (2002) DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol Cell 9:175-186.
31. 2/M transition. J Biol Chem 278:49196-49202.
32. Gaiddon C, et al. (2003) Cyclin-dependent kinases phosphorylate p73 at threonine 86 in a cell cycle-dependent manner and negatively regulate p73. J Biol Chem 278:27421-27431.
33. Gong JG, et al. (1999) The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399:806-809.
34. Agami R, Blandino G, Oren M, Shaul Y (1999) Interaction of c-Abl and p73 α and their collaboration to induce apoptosis. Nature 399:809-813.
35. Watson IR, Blanch A, Lin DC, Ohh M, Irwin MS (2006) Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function. J Biol Chem 281:34096-34103.
36. Dumaz N, Milne DM, Meek DW (1999) Protein kinase CK1 is a p53-threonine 18 kinase which requires prior phosphorylation of serine 15. FEBS Lett 463:312-316.
37. Sakaguchi K, et al. (2000) Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase: Effect on Mdm2 binding. J Biol Chem 275:9278-9283.
38. Malaguarnera R, et al. (2008) TAp73 α increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation. Mol Cancer Res 6:64-77.
39. Weinberg RL, Veprintsev DB, Fersht AR (2004) Cooperative binding of tetrameric p53 to DNA. J Mol Biol 341:1145-1159.
40. Hajduk PJ, et al. (1997) NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein. J Med Chem 40:3144-3150.
41. Chenna R, et al. (2003) Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res 31:3497-3500.
42. Clamp M, Cuff J, Searle SM, Barton GJ (2004) The Jalview Java alignment editor. Bioinformatics 20:426-427.